ZA200107143B - Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders. - Google Patents

Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.

Info

Publication number
ZA200107143B
ZA200107143B ZA200107143A ZA200107143A ZA200107143B ZA 200107143 B ZA200107143 B ZA 200107143B ZA 200107143 A ZA200107143 A ZA 200107143A ZA 200107143 A ZA200107143 A ZA 200107143A ZA 200107143 B ZA200107143 B ZA 200107143B
Authority
ZA
South Africa
Prior art keywords
disorders
saredutant
treat
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
ZA200107143A
Other languages
English (en)
Inventor
Xavier Emonds-Alt
Philippe Soubrie
Regis Steinberg
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of ZA200107143B publication Critical patent/ZA200107143B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
ZA200107143A 1999-04-27 2001-08-29 Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders. ZA200107143B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905338A FR2792835B3 (fr) 1999-04-27 1999-04-27 Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Publications (1)

Publication Number Publication Date
ZA200107143B true ZA200107143B (en) 2002-10-30

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200107143A ZA200107143B (en) 1999-04-27 2001-08-29 Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.

Country Status (32)

Country Link
US (3) US6573281B1 (cs)
EP (1) EP1173179B1 (cs)
JP (1) JP2002542281A (cs)
KR (1) KR20020001850A (cs)
CN (1) CN1172669C (cs)
AR (1) AR023597A1 (cs)
AT (1) ATE234617T1 (cs)
AU (1) AU764304B2 (cs)
BG (1) BG65472B1 (cs)
BR (1) BR0010006A (cs)
CA (1) CA2370834C (cs)
CZ (1) CZ294904B6 (cs)
DE (1) DE60001725T2 (cs)
DK (1) DK1173179T3 (cs)
EE (1) EE05211B1 (cs)
ES (1) ES2193065T3 (cs)
FR (1) FR2792835B3 (cs)
HU (1) HUP0200969A3 (cs)
IL (1) IL145269A0 (cs)
MX (1) MXPA01010904A (cs)
NO (1) NO20015228L (cs)
NZ (1) NZ513851A (cs)
PL (1) PL196479B1 (cs)
PT (1) PT1173179E (cs)
RU (1) RU2238726C2 (cs)
SI (1) SI1173179T1 (cs)
SK (1) SK285459B6 (cs)
TR (1) TR200102512T2 (cs)
TW (1) TWI225399B (cs)
UA (1) UA69441C2 (cs)
WO (1) WO2000064423A2 (cs)
ZA (1) ZA200107143B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
EP1278719B1 (en) * 2000-04-06 2005-11-02 AstraZeneca AB Naphthamide neurokinin antagonists for use as medicaments
ES2307605T3 (es) * 2000-04-06 2008-12-01 Astrazeneca Ab Nuevos antagonistas de neuroquininas para su uso como medicamentos.
GB0019008D0 (en) 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (sv) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
FR2904221B1 (fr) * 2006-07-31 2008-09-12 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et la fluoxetine.
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
ATE549316T1 (de) * 2007-09-14 2012-03-15 Hoffmann La Roche Piperidinderivate als nk3-rezeptorantagonisten
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2695626B1 (fr) * 1992-09-17 1994-12-02 Lebroch Yannick Dispositif de gobelet adaptable sur un conteneur de boisson.
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Also Published As

Publication number Publication date
AU4303400A (en) 2000-11-10
SK285459B6 (sk) 2007-02-01
US7390823B2 (en) 2008-06-24
EP1173179A2 (fr) 2002-01-23
JP2002542281A (ja) 2002-12-10
BG105962A (en) 2002-05-31
CN1172669C (zh) 2004-10-27
TWI225399B (en) 2004-12-21
US20030176462A1 (en) 2003-09-18
US6573281B1 (en) 2003-06-03
MXPA01010904A (es) 2002-06-21
WO2000064423A3 (fr) 2001-04-19
HUP0200969A2 (hu) 2002-07-29
AR023597A1 (es) 2002-09-04
EP1173179B1 (fr) 2003-03-19
BR0010006A (pt) 2002-01-15
IL145269A0 (en) 2002-06-30
EE200100553A (et) 2003-02-17
NO20015228L (no) 2001-12-21
SK15472001A3 (sk) 2002-03-05
PT1173179E (pt) 2003-06-30
PL351922A1 (en) 2003-06-30
SI1173179T1 (en) 2003-06-30
WO2000064423A2 (fr) 2000-11-02
ATE234617T1 (de) 2003-04-15
PL196479B1 (pl) 2008-01-31
HUP0200969A3 (en) 2004-03-01
RU2238726C2 (ru) 2004-10-27
NZ513851A (en) 2003-04-29
UA69441C2 (uk) 2004-09-15
CA2370834C (en) 2007-09-25
DE60001725T2 (de) 2004-02-05
CN1348371A (zh) 2002-05-08
KR20020001850A (ko) 2002-01-09
US20080227818A1 (en) 2008-09-18
HK1041821A1 (en) 2002-07-26
TR200102512T2 (tr) 2002-04-22
ES2193065T3 (es) 2003-11-01
FR2792835B3 (fr) 2001-05-25
EE05211B1 (et) 2009-10-15
CA2370834A1 (en) 2000-11-02
AU764304B2 (en) 2003-08-14
NO20015228D0 (no) 2001-10-25
BG65472B1 (bg) 2008-09-30
CZ20013812A3 (cs) 2002-02-13
FR2792835A1 (fr) 2000-11-03
DK1173179T3 (da) 2003-07-14
DE60001725D1 (de) 2003-04-24
CZ294904B6 (cs) 2005-04-13

Similar Documents

Publication Publication Date Title
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
PT1202722E (pt) Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
WO2003015779A3 (de) Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
NZ337827A (en) Use of GluR5 receptor antagonists in the manufacture of medicaments for treating pain
WO1999044608A8 (en) New use
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
EP1440689A3 (en) Treatment of neurotic disorders
AU1028601A (en) Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
WO2005007149A8 (de) Ambroxol für die behandlung akuter schmerzen
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
JP2002542281A5 (cs)
RU2001124802A (ru) Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств
MXPA02012894A (es) Catecoles nitrados substituidos, su uso en el tratamiento de algunos trastornos del sistema nervioso central y periferico y composiciones farmaceuticas que los contienen.
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
PL356001A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
ZA200110073B (en) 14β-H-Sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments.
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
WO2000067733A3 (de) Medikament zur therapie der männlichen infertilität
ZA981918B (en) Use of 2,3,4,5-tetrahydro-1H-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders